The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.145
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.15 (7.246%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.145
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Nov 2016 07:00

RNS Number : 6800O
Immupharma PLC
09 November 2016
 

RNS : FOR IMMEDIATE RELEASE

9 NOVEMBER 2016

 

 

 

NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma's total voting rights.

 

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General as one of the new significant and major institutional investors which participated in ImmuPharma's recent successful vendor placing. One of the Board's priorities is to maintain and strengthen our shareholder base. We are therefore delighted that such a highly regarded institution as Legal & General has demonstrated its support for ImmuPharma."

 

 

Full disclosure of the TR1 is shown below:

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Immupharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

Other (please specify):

 

Placement of 2,857,143 shares

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

 

Legal & General Assurance Society Limited (LGAS & LGPL)

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

21 October 2016

6. Date on which issuer notified:

28 October 2016

7. Threshold(s) that is/are crossed orreached:

 

L&G (Above 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.10

First notification under DTR Sourcebook

 4,285,714

 4,285,714

-

3.43%

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 4,285,714

 

3.43%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) (Below 5% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (Below 5% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) (Below 5% = Total Position)

Legal & General Group Plc (Direct) (L&G) (4,285,714, 3.43% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (4,285,714, 3.43% = LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) (4,285,714, 3.43% = LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of 124,638,362

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

 

 

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

Panmure, Gordon & Co., (NOMAD & Broker)

 

+44 (0) 20 7886 2500

Freddy Crossley, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, John Howes, Corporate Broking

 

 

 

 

 

+44 (0)20 3861 6625

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBVLLBQFFLFBQ
Date   Source Headline
4th May 20167:00 amRNSFinal Results
26th Apr 20167:00 amRNSNotice of Results
22nd Apr 20169:50 amRNSHolding(s) in Company
9th Mar 20167:00 amRNSFirst European Site Opens - Patient Recruitment
8th Mar 201611:10 amRNSHolding(s) in Company
7th Mar 20163:31 pmRNSHolding(s) in Company
1st Mar 20167:00 amRNSEIS and VCT Qualifying Status and Issue of Equity
29th Feb 20168:02 amRNSHolding(s) in Company
24th Feb 201612:35 pmRNSIssue of Equity
22nd Feb 20161:39 pmRNSResult of GM
15th Feb 20167:00 amRNSUS PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 201612:22 pmRNSPlacing and Subscription Raises £8.3 million
5th Feb 20167:00 amRNSProposed Placing and Subscription
21st Jan 20165:33 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 20157:00 amRNSUpdate on the progress of Lupuzor
30th Nov 201511:55 amRNSHolding(s) in Company
4th Nov 20158:26 amRNSLupuzor Phase III Pivotal Trial Update
4th Nov 20157:00 amRNSLupuzor Phase III Pivotal Trial Update
23rd Oct 20157:00 amRNSDirectorate Change
30th Sep 20157:05 amRNSDirectorate Change
30th Sep 20157:00 amRNSInterim Results
29th Jul 20157:00 amRNSRichard Warr
27th Jul 20157:00 amRNSTERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 20157:00 amRNSLupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 201512:50 pmRNSResult of AGM
6th May 20153:44 pmRNSAnnual Report & Accounts
6th May 20157:02 amRNSInterim Board Change
30th Apr 20157:05 amRNSDirectorate Change
30th Apr 20157:00 amRNSPreliminary Results
11th Feb 201512:02 pmRNSCANCER UPDATE: IPP-204106
27th Jan 20157:00 amRNSEnterprise Investment Scheme Status
22nd Jan 20157:00 amRNSCollaboration Agreement with Simbec-Orion
30th Oct 201411:10 amRNSHolding(s) in Company
28th Oct 20147:00 amRNSHolding(s) in Company
21st Oct 20147:00 amRNSAdditional Listing - Conditional Placing
20th Oct 20147:00 amRNSImmuPharma awarded EUR400,000 Grant
30th Sep 20147:05 amRNSHalf Yearly Report
30th Sep 20147:00 amRNSLupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 20141:11 pmRNSResult of AGM
27th Jun 20147:00 amRNSAccess to pioneering research in Bordeaux France
16th Jun 20147:00 amRNSNEW NUCANT PATENTS
23rd May 20147:00 amRNSAnnual Financial Report
21st May 20147:00 amRNSPreliminary Results
6th May 201412:47 pmRNSDr. Sylviane Muller - Presentation Abstract
23rd Apr 20147:00 amRNSDr. S Muller, founder of Lupuzor presentation.
11th Apr 20147:00 amRNSImmuPharma Sponsors the 2014 European Lupus Confer
14th Oct 20137:00 amRNSAdditional Listing
27th Sep 20137:00 amRNSHalf Yearly Report
13th Aug 20137:00 amRNSUPDATE CANCER PROGRAMME IPP-204106

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.